Monitor Blood Glucose Without Pricking Your Finger

Monitoring blood glucose without pricking your finger is now a practical reality for many people living with diabetes in the UK. Continuous glucose monitors (CGMs) and flash glucose sensors measure glucose in the fluid beneath the skin, providing a continuous or on-demand picture of levels throughout the day and night. These technologies have transformed diabetes management, reducing the burden of repeated fingerstick testing and alerting users to dangerous trends before they become serious. This article explains how these devices work, which are available on the NHS, how accurate they are, who benefits most, and what costs and limitations to consider.

Can you check your blood sugar without pricking your finger?

Yes, CGMs and flash glucose sensors measure glucose in interstitial fluid beneath the skin, substantially reducing or largely eliminating the need for routine fingerprick testing, though a confirmatory fingerprick is still advised when readings do not match symptoms.

Yes, it is possible to monitor blood glucose without pricking your finger, using devices called continuous glucose monitors (CGMs) or flash glucose sensors, both of which measure glucose in the fluid just beneath the skin rather than in a blood sample. These technologies have transformed diabetes management for many people in the UK, reducing the burden of repeated fingerstick testing while providing a continuous or on-demand picture of glucose levels throughout the day and night.

Traditional blood glucose monitoring requires a lancet to pierce the fingertip, a test strip, and a handheld meter. While this remains accurate and widely used, it only captures a single moment in time and can be uncomfortable when performed multiple times daily. Sensor-based alternatives offer a more continuous view, alerting users to rising or falling glucose trends before levels become dangerously high or low.

It is worth noting that some CGM systems still recommend a confirmatory fingerprick test in certain situations, such as when symptoms do not match the sensor reading, during rapid glucose changes, or during illness. Whether a device is suitable for making insulin dosing decisions without a confirmatory fingerprick depends on the device's intended use as described in its instructions for use (IFU) and CE or UKCA marking. Many modern devices have been assessed as suitable for insulin dosing decisions without routine confirmatory testing, meaning the need for fingerpricks can be substantially reduced or, for some users, largely eliminated in day-to-day use. Users should always follow the guidance in their specific device IFU and seek advice from their diabetes care team.

For people managing type 1 or type 2 diabetes, or for those monitoring glucose for other clinical reasons, discussing sensor-based options with a GP or diabetes specialist nurse is a sensible first step. Eligibility for NHS provision depends on clinical criteria set out in NICE guidance, which are covered in a later section.

How do continuous glucose monitors work in the UK?

CGMs use a small flexible sensor filament inserted just under the skin to measure interstitial glucose every one to five minutes, transmitting readings wirelessly to a reader or smartphone app with trend arrows indicating whether levels are rising or falling.

Continuous glucose monitors work by measuring glucose concentrations in interstitial fluid, the fluid that surrounds cells in the tissue just beneath the skin, using a small flexible sensor filament inserted just under the surface. The sensor communicates wirelessly with a reader device or a smartphone app, providing glucose readings every one to five minutes depending on the system, along with trend arrows that indicate whether levels are rising, falling, or stable.

There are two broad categories available in the UK. Real-time CGMs transmit readings continuously and can trigger audible or vibration alerts when glucose falls below or rises above user-defined thresholds. Flash glucose monitoring systems, such as the FreeStyle Libre range manufactured by Abbott, require the user to actively scan the sensor with a reader or compatible smartphone to obtain a reading, though newer versions of the FreeStyle Libre also include optional real-time alerts.

The sensor filament is typically replaced every seven to fifteen days, depending on the device; users should check the IFU for their specific system. Insertion is performed by the user using a small applicator and is generally described as minimally uncomfortable. The sensor is worn on the upper arm, abdomen, or another site approved for that device, and most are water-resistant for everyday activities including showering and swimming, though the degree of water resistance varies by product and should be confirmed in the device IFU.

Because interstitial glucose lags slightly behind blood glucose, particularly during rapid changes such as after eating or during exercise, users are advised to interpret trend data alongside the numerical reading rather than relying on the number alone. CGM and flash glucose devices placed on the UK market carry a CE or UKCA mark, indicating they have undergone the required conformity assessment, and are registered with the MHRA as the UK competent authority for medical devices.^[14][15]

Which finger-prick-free devices are available on the NHS?

The FreeStyle Libre 2 and 3, Dexcom G7, and Dexcom ONE are among the CGM devices available on NHS prescription for eligible patients, subject to NICE guidance and local ICB or Health Board commissioning decisions.

Several CGM and flash glucose monitoring devices are available on the NHS in England, Scotland, Wales, and Northern Ireland, though the specific products commissioned and the eligibility criteria vary between the four nations and between local Integrated Care Boards (ICBs) in England and Health Boards in the devolved nations. NICE guidance, including NG17 (type 1 diabetes in adults) and NG18 (diabetes in children and young people), recommends real-time CGM for people with type 1 diabetes across age groups.^[1][2] NICE NG3 covers CGM use in pregnancy, and NG28 addresses when CGM or flash monitoring may be appropriate for people with type 2 diabetes.^[5][6] NICE TA943 specifically addresses hybrid closed-loop systems, which combine CGM with insulin pump therapy, and is a separate recommendation from standalone CGM provision.^[10]

The FreeStyle Libre 2 and FreeStyle Libre 3 (Abbott) are among the most widely prescribed flash and real-time CGM systems in the UK. The Dexcom G7 and Dexcom ONE are real-time CGMs also available on NHS prescription for eligible patients. The Medtronic Guardian Sensor system is used in conjunction with certain insulin pump therapies. Availability of specific devices on NHS prescription is subject to local ICB or Health Board commissioning decisions and local training and supply arrangements, meaning that a device recommended by NICE may not yet be funded in every area.

For people with type 2 diabetes, NHS access to CGM is more restricted and is generally limited to those using insulin, particularly those at risk of hypoglycaemia, in line with NICE NG28.^[7][8] People with gestational diabetes or other conditions affecting glucose regulation may also be considered on clinical grounds in line with NICE NG3.

Bolt Pharmacy is a GPhC-registered UK online pharmacy offering online consultations with prescriber review and pharmacist support, where clinically appropriate options for diabetes management may be discussed. Anyone uncertain about their eligibility for NHS sensor provision should speak to their GP or diabetes care team in the first instance.

How accurate are sensor-based glucose monitors compared to traditional testing?

Modern CGM devices are clinically accurate enough for insulin dosing decisions for their intended use, though interstitial glucose lags five to fifteen minutes behind blood glucose during rapid changes, and a confirmatory fingerprick is recommended when readings do not match symptoms.

Modern CGM and flash glucose sensors are clinically accurate enough for insulin dosing decisions in most circumstances for devices whose IFU supports this use, though they measure interstitial glucose rather than blood glucose directly, which introduces a physiological lag of approximately five to fifteen minutes. Accuracy for CGM devices is typically reported using mean absolute relative difference (MARD), and leading devices such as the FreeStyle Libre 3 and Dexcom G7 have published accuracy data in their respective IFUs and in peer-reviewed literature demonstrating clinically acceptable performance for their intended use.^[23][24] Users should consult the IFU for their specific device for accuracy specifications.

Accuracy can be affected by several factors:

• Rapid glucose changes: During fast rises or falls, the interstitial reading may lag behind the true blood glucose level, making trend arrows particularly important.

• Sensor site and insertion: Compression of the sensor during sleep or exercise can temporarily affect readings.

• Certain medications: Paracetamol at high doses has been shown to interfere with some older sensor technologies; users should check the interference information in their device IFU, as many current devices have addressed this.^[17][18]

• Calibration requirements: Some systems require periodic fingerprick calibration to maintain accuracy, though others are factory-calibrated and do not.^[22][12]

CGM and flash glucose devices placed on the UK market carry a CE or UKCA mark following conformity assessment and are registered with the MHRA. The EMA is not involved in the authorisation of medical devices.

For most day-to-day management decisions, the accuracy of current CE- or UKCA-marked CGM devices is considered clinically acceptable. However, if a sensor reading does not match how a person feels, or if a hypoglycaemic episode is suspected, a confirmatory fingerprick blood glucose test remains the recommended course of action. Users should always follow the instructions provided with their specific device and seek guidance from their diabetes care team if they have concerns about sensor performance.

Who is most likely to benefit from a CGM or flash glucose sensor?

People with type 1 diabetes benefit most, as supported by NICE NG17 and NG18, though those with insulin-treated type 2 diabetes, hypoglycaemia unawareness, or pre-existing diabetes in pregnancy also benefit significantly.

People with type 1 diabetes are most likely to benefit from continuous or flash glucose monitoring, as they require frequent glucose checks to manage insulin doses safely and are at significant risk of both hypoglycaemia and hyperglycaemia. NICE NG17 and NG18 support CGM use in adults and in children and young people with type 1 diabetes respectively, recognising that real-time alerts can reduce the frequency and severity of hypoglycaemic episodes and improve overall glycaemic control as measured by HbA1c.^[1][2]

Beyond type 1 diabetes, the following groups may also benefit substantially:

• People with type 2 diabetes using insulin, particularly those who experience hypoglycaemia unawareness or who require multiple daily injections, in line with NICE NG28.

• Pregnant women with pre-existing diabetes, for whom tight glucose control is important for maternal and fetal outcomes, in line with NICE NG3.

• People with hypoglycaemia unawareness, a condition in which the usual warning symptoms of low blood sugar are absent or blunted, making real-time alerts especially valuable.

• Children and young people with diabetes, where CGM can reduce the disruption of frequent fingerprick testing during school and activities, as supported by NICE NG18.

People with type 2 diabetes who are managing their condition through diet, exercise, or non-insulin medication alone are less likely to be offered NHS-funded CGM at present, though this area of guidance continues to evolve. Some individuals in this group choose to self-fund sensor use for motivational or educational purposes, which is discussed further in the following section.

Anyone considering CGM should discuss their individual circumstances with their GP or diabetes specialist, as clinical suitability, device choice, and training requirements all vary between patients.

What are the costs and limitations of sensor-based glucose monitoring?

Out-of-pocket sensor costs are significant for those not eligible for NHS provision, and limitations include interstitial lag, sensor lifespan of seven to fifteen days, potential skin reactions, device compatibility issues, and a learning curve requiring adequate training.

For those who do not qualify for NHS-funded CGM, the out-of-pocket cost of sensor-based glucose monitoring can be significant. Sensor costs vary by device and supplier, and because prices change regularly, it is advisable to check current pricing directly with pharmacies or device manufacturers rather than relying on any single quoted figure. Private prescription costs are separate from NHS prescription charges, which differ across the four UK nations and are updated periodically; current NHS prescription charge information for England and the devolved nations is available on the NHS.UK website.

Limitations of current CGM and flash glucose technology include:

• Sensor lifespan: Most sensors must be replaced every seven to fifteen days, creating ongoing consumable costs and the need for regular re-insertion; replacement intervals vary by device and should be confirmed in the device IFU.

• Interstitial lag: As described earlier, readings during rapid glucose changes may not reflect blood glucose in real time, requiring users to interpret trend data carefully.

• Skin reactions: Some users experience localised skin irritation or adhesive reactions at the sensor site, which may limit wearability.

• Device compatibility: Not all sensors are compatible with all smartphones or insulin pumps, and software updates can occasionally affect functionality; users should check compatibility information in their device IFU.

• Imaging and other procedures: Some devices may need to be removed before certain medical procedures such as MRI, CT, or diathermy; users should check their device IFU and inform healthcare professionals before any such procedure.

• Learning curve: Getting the most from CGM data requires education and support, and without adequate training, users may misinterpret readings or experience alert fatigue from frequent alarms.

There are also truly non-invasive glucose monitoring technologies in development, including devices that aim to measure glucose through the skin using optical or radiofrequency methods without any sensor insertion. However, as of the time of writing, no such device has received CE or UKCA marking for clinical glucose monitoring in the UK. Suspected problems with any CE- or UKCA-marked medical device should be reported via the MHRA Yellow Card scheme at yellowcard.^[16]mhra.gov.uk.

Scientific References

1. Type 1 diabetes in adults: diagnosis and management (NG17) – recommendations.
2. Resource impact report: continuous glucose monitoring – NG17/NG18.
3. Diabetes (type 1 and type 2) in children and young people: diagnosis and management (NG18).
4. Diabetes (type 1 and type 2) in children and young people: rationale and impact (NG18).
5. Diabetes in pregnancy: management from preconception to the postnatal period (NG3).
6. Diabetes in pregnancy: management from preconception to the postnatal period – recommendations (NG3).
7. Type 2 diabetes in adults: management (NG28).
8. Blood glucose management – Type 2 diabetes in adults (NG28).
9. Continuous glucose monitoring for adults who use insulin and need help monitoring their blood glucose (QS209).
10. Hybrid closed loop systems for managing blood glucose levels in type 1 diabetes (TA943).
11. The technology: FreeStyle Libre for glucose monitoring (MIB110).
12. Diabetes mellitus, diagnostic and monitoring devices.
13. Continuous glucose monitoring and hybrid closed loop for diabetes.
14. Regulating medical devices in the UK.
15. Medical devices: conformity assessment and the UKCA mark.
16. Report a problem with a medicine or medical device (Yellow Card scheme).
17. Interference of Intravenous Acetaminophen with Continuous Glucose Monitoring System.
18. Laboratory Protocol and Pilot Results for Dynamic Interference Testing of Continuous Glucose Monitoring Sensors. Journal of Diabetes Science and Technology.
19. A Model of Acetaminophen Pharmacokinetics and its Effect on Continuous Glucose Monitoring Sensor Measurements. IEEE EMBC.
20. Breaking through lag: enhancing intradermal electro-osmotic flow and the future of delay-free continuous glucose monitoring. Frontiers in Bioengineering and Biotechnology.
21. Consensus Considerations and Good Practice Points for Use of Continuous Glucose Monitoring Systems in Hospital Settings. Diabetes Care.
22. Calibration algorithms for continuous glucose monitoring systems based on interstitial fluid sensing. Biosensors & Bioelectronics.
23. Pediatric Inpatient Continuous Glucose Monitoring: Development and Implementation of a Hospital Policy for Accuracy-Validated Insulin Dosing. Diabetes Technology & Therapeutics.
24. Impact of Ascorbic Acid and Exercise on Accuracy of a Glucose Monitoring System with GDH-FAD Technology in Adult Patients with Type 1 Diabetes Mellitus. Diabetes Therapy.
25. Accuracy and Safety of the LinX Continuous Glucose Monitoring System in Adults With Diabetes. Diabetes, Obesity & Metabolism.

Frequently Asked Questions